8-K: Supernus Pharmaceuticals to Acquire Sage Therapeutics in Up to $795 Million Deal, Bolstering Neuropsychiatry Portfolio with ZURZUVAE

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Sage Therapeutics, Inc. for an upfront cash payment of $8.50 per share plus a contingent value right of up to $3.50 per share, totaling up to $12.00 per share, aiming to expand its CNS product offerings and achieve significant synergies.

Summary

• Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. through a tender offer followed by a merger.
• The total consideration for Sage shareholders is $8.50 per share in cash upfront, plus one non-tradable Contingent Value Right (CVR) worth up to $3.50 per share, for an aggregate potential value of up to $12.00 per share.
• The total transaction value is approximately $561 million in upfront cash and up to $234 million in CVR payments, for a maximum aggregate of approximately $795 million.
• The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions, including regulatory approvals and the tender of a majority of Sage's outstanding common stock.
• Sage's Board of Directors has unanimously approved the merger agreement and recommends that stockholders tender their shares.
• The primary asset acquired is ZURZUVAE (zuranolone) capsules CIV, the first and only FDA-approved oral medicine for the treatment of adults with postpartum depression (PPD).
• Supernus will report collaboration revenue from ZURZUVAE, representing 50% of the net revenue recorded by Biogen, Inc. under an existing collaboration agreement.
• For the full year 2024, collaboration revenue from ZURZUVAE net sales was $36.1 million, and for the first quarter of 2025, it was $13.8 million.
• Outstanding 'in-the-money' Company Options, Company RSUs, and vested Company PSUs will be fully vested and converted into a cash payment based on the $8.50 Closing Amount plus one CVR per share.
• Company Options with an exercise price equal to or greater than $8.50 will be cancelled without payment.
• Unvested Company PSUs will be deemed vested and converted into a cash payment based on the $8.50 Closing Amount plus one CVR per share.
• The Company ESPP's current offering period will be the final one, with no new participants or increased payroll deductions, and outstanding purchase rights will be exercised no later than five business days prior to the Effective Time, after which the ESPP will terminate.
• The CVRs are not transferable except under limited circumstances (e.g., death, court order) and will not be registered or listed for trading.
• The parties intend to treat CVRs received for shares as additional consideration for tax purposes, and CVRs for equity awards as wages.

Sentiment

Score: 8

Explanation: The sentiment is highly positive, driven by the definitive acquisition agreement, the strategic benefits for Supernus (revenue growth, diversification, synergies, accretive nature), and the Sage Board's strong recommendation, indicating a favorable outcome for its shareholders. The CVR adds potential upside, though its contingency introduces a minor element of uncertainty.

Positives

• The acquisition is expected to accelerate Supernus's midto long-term revenue and cash flow growth.
• It strengthens Supernus's leading presence in neuropsychiatric conditions by adding ZURZUVAE, an innovative commercial product, and a novel CNS discovery platform.
• The transaction is anticipated to be significantly accretive to Supernus in 2026.
• Supernus expects to achieve potential cost synergies of up to $200 million on an annual basis due to a strong fit with existing infrastructure.
• The acquisition diversifies and increases Supernus's revenue base and cash flow, adding a fourth growth product alongside Qelbree, ONAPGOTM, and GOCOVRI.
• Sage's Board of Directors determined the transaction is fair to and in the best interest of the Company and its stockholders, recommending they tender their shares.

Negatives

• Holders of Company Options with a per share exercise price equal to or greater than $8.50 will have their options cancelled without payment.
• The CVRs are non-tradable and their value is contingent on specific milestones, with no assurance that these milestones will be achieved by their corresponding deadline dates.

Risks

• Uncertainties exist regarding the timing of the tender offer and the merger.
• There is a risk that not enough Sage stockholders will tender their shares in the offer.
• Holders of CVRs may not receive any payments if the specified milestones are not achieved by their corresponding deadline dates.
• The possibility of competing offers for Sage could disrupt the transaction.
• Various closing conditions for the transactions may not be satisfied or waived, including potential prohibition, delay, or refusal of approval by a governmental entity.
• The transactions could negatively impact relationships with employees, other business partners, or governmental entities.
• Difficulty in predicting the timing or outcome of U.S. Food and Drug Administration approvals or actions.
• The impact of competitive products and pricing could affect ZURZUVAE's market performance.
• Supernus may not realize the full potential benefits of the transactions.
• Other business effects, including industry, economic, or political conditions outside the companies' control, could adversely affect outcomes.
• Transaction costs and actual or contingent liabilities could impact financial results.
• Sage's (and subsequently Supernus's) launch and commercialization efforts for ZURZUVAE for PPD may not be successful.
• ZURZUVAE may not achieve the clinical benefit, clinical use, or market acceptance expected, potentially due to reimbursement, market access, process-related issues, or market competition.
• ZURZUVAE may never become the standard of care for women with PPD.

Future Outlook

The acquisition is expected to accelerate Supernus's midto long-term revenue and cash flow growth, significantly diversify its revenue base, and be significantly accretive in 2026. Supernus aims to build on ZURZUVAE's U.S. growth momentum and collaboration with Biogen. The future value for Sage shareholders includes potential CVR payments contingent on ZURZUVAE achieving specific sales milestones in the U.S. and regulatory approval and first commercial sale in Japan by specified deadlines.

Management Comments

• Jack Khattar, President and CEO of Supernus Pharmaceuticals: "This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. ZURZUVAE aligns with our focus of acquiring novel value-enhancing and clinically-differentiated medicines to treat CNS conditions. We have a proven track record of strong commercial execution, and we look forward to building on ZURZUVAE’s U.S. growth momentum and collaboration with Biogen, so that more women with postpartum depression can benefit from this novel treatment."
• Barry Greene, Chief Executive Officer, Sage Therapeutics: "Since our founding, Sage Therapeutics has been committed to pioneering new solutions in brain health, one of the most complex and underserved areas of medicine. We are proud of what we’ve accomplished, including successfully developing and commercializing ZURZUVAE, the first and only oral treatment for women with postpartum depression. This transaction follows a comprehensive strategic review by our Board of Directors, and I am confident this deal maximizes value for shareholders. I want to express my deepest gratitude to the Sage team for their unwavering commitment to brain health and improving the lives of patients. We look forward to our next chapter with Supernus."

Industry Context

This acquisition reflects a trend of consolidation within the pharmaceutical industry, particularly in specialized therapeutic areas like central nervous system (CNS) disorders and mental health. Supernus, already focused on CNS, is expanding its portfolio with a newly approved, innovative oral treatment for postpartum depression, ZURZUVAE. This move allows Supernus to leverage its existing commercial infrastructure and expertise in CNS, potentially enhancing market penetration for ZURZUVAE and diversifying its revenue streams beyond its current growth products (Qelbree, ONAPGOTM, GOCOVRI). The deal also highlights the value placed on novel, FDA-approved therapies addressing unmet medical needs, even if their initial commercial ramp-up is slower than anticipated.

Comparison to Industry Standards

• The acquisition price of up to $12.00 per share for Sage Therapeutics, a company with a recently approved but early-stage commercial product (ZURZUVAE), can be compared to other M&A activities in the neuropsychiatry or rare disease space, where valuations often reflect pipeline potential and market exclusivity rather than immediate profitability.
• The inclusion of a Contingent Value Right (CVR) is a common mechanism in biotech acquisitions, especially for companies with products in early commercialization or late-stage development. This structure allows the buyer (Supernus) to mitigate risk by tying a portion of the purchase price to the future commercial success of ZURZUVAE, while providing Sage shareholders with potential upside.
• The collaboration revenue from ZURZUVAE, where Supernus will receive 50% of net revenue recorded by Biogen, Inc., is a specific financial arrangement. This type of revenue-sharing model is typical in pharmaceutical co-commercialization agreements, such as those seen between larger pharmaceutical companies and smaller biotech firms, where the larger partner (Biogen) handles broader commercialization efforts.
• The stated goal of achieving up to $200 million in annual cost synergies suggests that Supernus anticipates significant operational efficiencies by integrating Sage's assets into its existing infrastructure, a common driver for acquisitions in the pharmaceutical sector.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions the possibility of stockholder litigation against Sage and/or its directors or officers relating to the transactions. Sage is obligated to notify Supernus, allow review and comment on filings, and consult on settlements for such litigation.

Stakeholder Impact

• **Shareholders (Sage):** Will receive $8.50 per share in cash upfront and potentially up to an additional $3.50 per share via CVRs, representing a premium and potential future upside tied to ZURZUVAE's commercial success. The Board recommends tendering shares.
• **Employees (Sage):** The Company will provide a conditional WARN Act notice, indicating potential mass layoffs if the sale is completed. Supernus will extend employment offers to selected employees, and non-continuing employees will receive severance benefits. Employee equity awards will be converted to cash and CVRs, with 'in-the-money' options, RSUs, and vested PSUs being cashed out and unvested PSUs vesting.
• **Customers/Patients:** The acquisition aims to build on ZURZUVAE's U.S. growth momentum, potentially increasing access to the oral treatment for postpartum depression.
• **Biogen, Inc.:** The existing collaboration agreement for ZURZUVAE will continue, with Supernus reporting 50% of the net revenue Biogen records for the product in the U.S.
• **Creditors:** The transaction is funded by Supernus's existing balance sheet cash and is not subject to a financing condition, suggesting a stable financial position for the combined entity.

Next Steps

• Supernus's Purchaser will commence the tender offer no later than 12 business days after June 13, 2025.
• The tender offer will expire 20 business days from its commencement date, unless extended.
• Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC upon commencement of the offer.
• Supernus and Purchaser will file Offer materials on Schedule TO with the SEC upon commencement of the offer.
• As soon as practicable following the consummation of the tender offer, Purchaser will merge with and into Sage Therapeutics, Inc.
• Supernus will provide revised full year 2025 financial guidance after the closing of the transaction, expected in the third quarter of 2025.
• Sage will provide a conditional WARN Act notice to its employees within ten business days after June 13, 2025, regarding potential mass layoffs if the sale is completed.

Key Dates

Recommendation

Keywords

Supernus Pharmaceuticals, Sage Therapeutics, Acquisition, Merger, Tender Offer, ZURZUVAE, Zuranolone, Postpartum Depression, PPD, Neuropsychiatry, CNS, Contingent Value Right, CVR, Biogen, Pharmaceuticals, Biotechnology, Drug Development, Commercialization, Healthcare, FDA Approval, Milestone Payments, Corporate Acquisition